ANORMED
AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic drugs for the treatment of hematology, human immunodeficiency virus (HIV), and oncology. Its lead drug product candidate include MOZOBIL, which is under phase III clinical trial is used for cancer patients undergoing stem cell transplantation; and AMD070, which is under phase Ib/IIa trial is used as a HIV entry inhibitor.
ANORMED
Industry:
Biotechnology Pharmaceutical
Founded:
1996-01-01
Address:
Langley, British Columbia, Canada
Country:
Canada
Status:
Active
Contact:
(604) 530-1057
Similar Organizations
Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs.
Dyax
Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet
Ercole Biotech
Ercole Biotech, Inc., a research stage biopharmaceutical company, creates oligonucleotide drugs that achieve their therapeutic effect by
Novel Laboratories
Novel Laboratories a pharmaceutical company, engages in the research, development, and manufacture of generic and branded products.
Nutra Pharma
Nutra Pharma Corp., a biopharmaceutical company, engages in the acquisition, licensing, and commercialization of pharmaceutical products
SyntheMed
SyntheMed is a biomaterials company engaged in the development and commercialization of medical devices for therapeutic applications.